Novo Nordisk A S
NVO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000353278
No open-market purchases or sales by Novo Nordisk A S insiders were filed in the last 90 days; 1,355 institutions reported holding it in 13F filings for Q2 2026, worth $15.7B in total; superinvestors Markel Group and Maverick Capital hold it.
Other share classesNONOF
13F holders, Q3 2025
Institutional positions in Novo Nordisk A S as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1,401
- −62 vs. Q2 2025
- Shares held
- 300.9M
- −7.02M (−2.3%) vs. Q2 2025
- Total value
- $16.7B
- −$4.54B (−21.4%) vs. Q2 2025
- New holders
- 161
- 505 more added
- Sold out
- 223
- 550 more reduced
23 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,355 | $15.7B |
| Q1 2026 | 1,278 | $12.0B |
| Q4 2025 | 1,421 | $16.0B |
| Q3 2025 | 1,401 | $16.7B |
| Q2 2025 | 1,486 | $21.3B |
| Q1 2025 | 1,535 | $22.5B |
| Q4 2024 | 1,670 | $29.1B |
| Q3 2024 | 1,787 | $39.7B |
| Q2 2024 | 1,866 | $47.9B |
| Q1 2024 | 1,745 | $41.8B |
| Q4 2023 | 1,512 | $32.2B |
| Q3 2023 | 1,308 | $27.4B |
| Q2 2023 | 1,198 | $23.2B |
| Q1 2023 | 1,148 | $22.1B |
| Q4 2022 | 1,050 | $19.4B |
| Q3 2022 | 908 | $13.8B |
| Q2 2022 | 934 | $16.4B |
| Q1 2022 | 902 | $15.2B |
| Q4 2021 | 887 | $14.7B |
| Q3 2021 | 806 | $12.7B |
| Q2 2021 | 737 | $11.0B |
| Q1 2021 | 708 | $8.87B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Novo Nordisk A S; share changes are against Q2 2025.